Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropidoxuridine with radiotherapy in IDH-wildtype glioblastoma with unmethylated MGMT
NCT06359379Phase 2Terminated
- Sponsor
- Shuttle Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ropidoxuridine in glioblastoma (GBM) (2 arms), sponsored by Shuttle Pharmaceuticals. Primary endpoints: Treatment-related Adverse Events, Radiographic Response Rate up to 100 months and 8 more. Started Sep 2024; status: terminated.
02
Drugs
ropidoxuridine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06359379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359379.